The QuickScreen™ One-Step Rapid Oxycodone Test is a rapid, visual, qualitative,
competitive binding immunoassay for the detection of Oxycodone
(Percodan, Percocet, Roxicodone, Oxycontin) and it's metabolites in human urine. The test provides a fast
confirmation of the presence of Oxycodone in the subject sample at a
minimum cutoff sensitivity level of 100 ng/ml
opiates, the sensitivity level set by the
National Institute on Drug Abuse and Departments of Health and Human Services
for this specific drug of abuse. While classified as an Opiate, the chemical
structure and metabolite of Oxycodone requires a separate Opiate test with a
substantially higher sensitivity detection level than that of the standard
Opiate drug test. Consequently, a positive test result will not only confirm
Oxycodone but other opiates as well. In this regard the Oxycodone test is not
Oxycodone specific but opiate specific being able to detect Oxycodone/opiate use
at the higher sensitivity level required while the 2000 ng/ml sensitivity level
of the standard opiate test would not detect Oxycodone. Note: Where indicated, any positive test should be confirmed using quantitative
methods by a qualified testing laboratory.
SUMMARY AND EXPLANATION OF THE TEST
Oxycodone, often called a narcotic, is an analgesic (pain reducer) which works by depressing the central nervous system. Oxycodone is abused for its opiate-like effects. In addition to its equal potency to morphine in analgesic effects, it is also equipotent to morphine in relieving abstinence symptoms from chronic opiate (heroin, morphine) use. For this reason, it is often used to alleviate or prevent the onset of opiate withdrawal by street users of heroin and methadone. In early studies by the Addiction Research Center in Lexington, Kentucky in the 1960's, it was discovered that the subjective and physiological effects of Oxycodone were greater than an equivalent dose of morphine in opiate substance abusers. Many dosage forms are available. Oxycodone’s behavioral effects can last up to 5 hours. The drug is most often administered orally. The sustained-release formula has a longer duration of action (8-12 hours). A recent study comparing controlled released products containing Oxycodone (Oxycontin) and morphine (MS Contin) reported that Oxycontin was twice as potent as MS Contin. As with other opiates, Oxycodone can also depress the respiratory system resulting in suffocation and death when overdosed. Doctors often prescribe Oxycodone for severe or chronic pain. Oxycodone is very addictive, both physically and psychologically. Use for only a short time normally results in addiction. Some physical indications of opiate use include: extreme loss of appetite and weight, cramps, nausea, vomiting, excessive scratching and complaint of itching, excessive sweating, constipation, pin-point pupils and watery eyes, reduced vision, drowsiness, euphoria, trance-like states, excessive thirst, tremors, twitching, irritability, hallucinations and lethargy. For comprehensive information on drug testing including typical half-life or drug detection periods see the Drug Testing FAQ.
The QuickScreen™ One-Step Rapid
Oxycodone Test utilizes a unique combination of monoclonal antibodies to
selectively identify Oxycodone and it's major metabolites in urine with a high degree of
sensitivity. The test kit is a rapid, visually read screening method that does not require
special instrumentation or training.
The QuickScreen™ One-Step Rapid
Oxycodone Test technology incorporates a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with an
opiate derivative immobilized on a porous membrane for limited antibody sites. This is the preferred scientific method for qualitative assay. In the assay procedure, urine mixes with labeled antibody-dye conjugate and migrates through test device. When
Oxycodone levels are below 100 ng/ml (the detection cutoff sensitivity of the test) unbound antibody-dye conjugate binds to immobilized antigen conjugate in the Test Zone ("T"), producing a pink-rose colored band that indicates a negative result. Conversely, when
Oxycodone levels are above the detection limit, antibody-dye conjugate binds to the free drug, forming an antigen-antibody-dye complex. The complex competes with immobilized antigen conjugate in the Test Zone, preventing the development of a pink-rose colored band. Regardless of the test result, a color band is produced in the Control Zone ("C") by a non-specific sandwich dye conjugate reaction. This band serves as a built-in quality control by demonstrating antibody recognition, verifying that the reagents are chemically active, and confirming that the test was performed correctly.
Test Device and Dropper Pipette individually sealed in foil pouch with complete instructions.
INTERPRETATION OF TEST RESULTS:
Positive: One (1) pink-rose band appears in the control zone and no band appears in the test zone. A positive result indicates the
Oxycodone level is 100 ng/ml or higher in the test urine sample.
The QuickScreen™ One-Step Rapid Oxycodone test is now available to professionals and individuals concerned with Oxycodone abuse. The test is one-step, fast, self-contained, individually packaged and can be performed any time the targeted drug use or abuse is suspected. The tests come in order units of five (5) individual tests at a cost per single diagnosis/screen of $4.00 for the minimum order unit. For testing situations where sample adulteration is suspect, a Rapid Urine Adulteration test is available.